Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

Stopped early · Not applicable · Has a placebo group

Conditions studied: Diabetic Macular Edema

In brief

Currently medications injected intravitreally in previously vitrectomized eyes have a very short half-life due to enhanced clearance of the drug. The use of the Ozurdex (dexamethasone) implant may allow sustained levels of steroid delivery to patients with diabetic macular edema that have undergone prior vitrectomy. The sustained steroid levels may lead to improved central retinal thickness measurements and improved visual acuity.

Key facts

Study ID
NCT01788475
Run by
Lahey Clinic
People needed
3
Starts
2013-02-22
Expected to finish
2014-11-12
Last updated by the study team
2020-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.